New Delhi [India], Jan 21 (ANI/PNN): Prochem Pharmaceutical Division, a globally recognized leader in API powder handling solutions for various domains, has merged with Tapasya, a proven granulation expert and solid formulation end-to-end solution provider for pharmaceutical, nutraceutical, and food industries. This will help the companies leverage their combined experience, manufacturing strengths and market knowledge and further strengthen Prochem’s efforts in its quest to deliver innovative and customized solutions to companies across all verticals, from active pharmaceutical ingredients to formulations in various geographies and many industries such as Specialty Chemicals, Agrochemicals, Nutraceuticals, etc.
The new business entity Prochem Tapasya Pvt Ltd will add value to create a comprehensive solution for the pharmaceutical and allied industries. The value proposition for clients will be in terms of executing projects at a faster pace and therefore a better return on investment. The alliance will also add value in terms of quality and cost optimization. “I am really excited about the possibilities offered by this merger of Tapasya with Prochem’s Pharmaceutical Division. As a leader in Granulation, Tapasya has its own distinctive strengths in the Pharmaceutical and FMCG industries, and its RMG, especially the Sizoner, is the most sold in the global market and widely used in all industries.Together we will be able to offer our customers in all verticals, innovative solutions that provide better performance and reliability in the future.We can grow to be stronger and have a better impact, a reflection of the ‘Make in India vision that we have been pursuing,” said Shashi Rai, director of Prochem.
Read also | Noida Shocker: Man driven in taxi for seven hours, robbed at gunpoint; Ongoing research.
“I envision the merger of Prochem with Tapasya as one with far-reaching impact. We now have the experience and bandwidth to address business across all vertical markets with solutions in powder handling and granulation. With India consolidating its leadership in Pharma and several other rapidly growing national markets, the demand for innovative solutions will continue to increase. Together we will be in the best position to seize this opportunity.” said Nitesh Srivastav, Head of Business, Prochem.
“This is a coming together of like minds to achieve something impactful and innovative. I firmly believe that an excellent opportunity exists, with our knowledge and presence in the market. Prochem is a proven market leader with a track record of offering waste management solutions powder. to renowned customers around the world. Our strengths, combined with theirs, will help us create next-generation solutions that are much needed by industries across all verticals,” said Dev Bakshi, CEO of Tapasya.
Read also | Rituparna Sengupta says his new black comedy film directed by Rajan Lallan Puri is a tribute to the late music director Bappi Lahiri.
Founded in 2007, Prochem relies on the three Cs of customization, conceptualization and commissioning to create innovative, trend-setting solutions, from raw material unloading to final product filling, that meet customer expectations. Widely recognized as one of the most innovative companies in the powder handling business, Prochem is committed to creating next-generation machines and solutions for companies across all domains.
Tapasya (OSD) Oral Solid Dosage is known for its contribution to various industries as a complete formulation solution provider and is a recognized provider of granulation and pelletizing technology. Established in 1962, the company has added immense value to the pelleting, drying, milling, mixing, micronizing, coating and granulating processes of companies in India and other parts of the world. Tapasya is a global market leader in the high shear mixer granulator space.
India is also one of the largest exporters of medicines, accounting for a third of the world’s pharmaceutical production in volume terms. The Indian pharmaceutical industry supplies more than 50% of the global demand for vaccines, 40% of the demand for generic medicines in the US and 25% of all medicines in the UK. India is also home to the largest number of US FDA compliant pharmaceutical units.
Together, the new business entity Prochem Tapasya Pvt Ltd is set to revolutionize the pharmaceutical industry from APIs to formulations through innovative product offerings. The merger to form a new entity, Prochem Tapasya, comes at a time when the Indian pharmaceutical industry is growing at a rapid pace. The domestic pharmaceutical market is projected to reach $65 billion by 2024 and $120-130 billion by 2030, offering tremendous growth potential for this joint venture.
This story is provided by PNN. ANI will not be responsible in any way for the content of this article. (ANI/PNN)
(This is an auto-generated, raw story from the syndicated news feed, the body of the content may not have been modified or edited by LatestLY staff)